

Agnes LABIGNE et al.  
Serial No. 08/211,312

Attorney Docket No.: 2356.0074

Claim 64, line 1, delete "A purified" and substitute therefor --The purified--.

Claim 65, line 1, delete "A purified" and substitute therefor --The purified--.

Claim 66, line 1, delete "A purified" and substitute therefor --The purified--.

Claim 67, line 1, delete "A purified" and substitute therefor --The purified--.

#### REMARKS

Applicants respectfully draw the Examiner's attention to the Revocation of Original Power of Attorney and Grant of New Power of Attorney filed by the assignee on June 19, 1997, naming the firm of Finnegan, Henderson, Farabow, Garrett, & Dunner, L.L.P. as attorneys of record (copy enclosed). The new Attorney Docket No. is 02356.0074-00000. If there is some reason that this Revocation and New Power has not been entered, applicants request that the Examiner notify the undersigned attorney.

Applicants have amended the specification to provide antecedent basis for the phrase "pharmaceutically acceptable carrier." This amendment is implicitly supported by the application and claims as filed and does not introduce new matter. Applicants have replaced the Abstract with one that more clearly reflects the claimed invention.

Applicants acknowledge with appreciation the Examiner's indication that claims 40-45, 53-55, and 62 are allowable.

Claims 63-67 stand rejected under 35 U.S.C. § 112, second paragraph, as allegedly indefinite. The Examiner has suggested that amending the claims to begin with the article "the" rather than "a" will overcome the rejection. Applicants have amended the claims accordingly and request that the rejection be withdrawn.

The Examiner has objected to the specification as failing to provide proper antecedent basis for the phrase "pharmaceutically acceptable carrier." Applicants have amended the

LAW OFFICES  
FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

Agnes LABIGNE et al.  
Serial No. 08/211,312

Attorney Docket No.: 2356.0074

specification to provide the necessary support for this phrase (see also, e.g., page 21, lines 15-30). Accordingly, applicants request that the objection be withdrawn. Although the Office Action does not specifically identify the basis for the rejection pending against claims 56-61, applicants believe that the amendment to the specification obviates that rejection. Accordingly, applicants request that the rejection of claims 56-61 be withdrawn.

The Examiner has objected to the Abstract because it contains a misspelling and because it does not properly reflect the content of the disclosure. Applicants have amended the Abstract to correct these problems and request withdrawal of the objection.


In view of the foregoing amendments, applicants respectfully submit that this application is now in condition for allowance. Reconsideration and allowance of the pending claims are earnestly solicited.

Applicants do not believe that any extension of time is required under § 1.136(a) to file this Amendment and Response. However, if an extension is required, such extension is hereby requested and any additional fees due in connection with the filing of this Amendment and Response, should be charged to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: July 28, 1998

By:   
Leslie A. McDonell  
Registration No. 34,872

LAW OFFICES  
FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N.W.  
WASHINGTON, DC 20005  
202-408-4000

Agnes LABIGNE et al.  
Serial No. 08/211,312

Attorney Docket No.: 2356.0074

ABSTRACT

12  
This invention relates to *Helicobacter* polypeptides, particularly UreE, UreF, UreG, UreH, and UreI, immunogenic fragments of those polypeptides, and compositions containing those polypeptides or fragments. This invention also relates to purified antibodies that bind to the polypeptides of this invention and to compositions comprising those antibodies.

08/24/3/2

58

ABSTRACT

Oligonucleotide sequences are disclosed specific to *H. pylori* urease and useful as DNA probes and primers in the detection of *H. pylori* infection in humans.

Sub  
F3